Robolution Capital (now part of 360 Capital Partners) closed its first investment in Chronocam in a $15 Million Series B round.
- Intel Capital, iBionext, CEA Investissement, Renault, and Robert Bosch Venture Capital also participated to the funding.
- This investment will help produ omega pas cher ctize and bring to market innovative bio-inspired vision t replica borse echnology that enables devices and machines to see.
Paris, October 24th 2016 – Chronocam SA, a developer of biologically-inspired vision sensors and computer vision solutions for automotive, IoT and other applications requiring vision processing, has raised $15 million in Series B financing. The funding comes from lead investor Intel Capital, along with iBionext, Robert Bosch Venture Capital GmbH, 360 Capital Partners (Robolution Capital fund), CEAi and Renault-Nissan Group.
Nicolas Autret, Partner of 360 Capital Partners / Robolution Capital, commented: “Chronocam’s technology is at the forefront of vision sensing and processing, and has the potential to revolutionize the world of conventional computer vision. The company has gathered a passionate and talented team to address an incredible business opportunity. Chronocam brings to the market the right technology at the right time. 360 Capital Partners, managing Robolution Capital fund, is thrilled to join the company as it continues to drive change and growth.”
The funds raised will be used by Chronocam to continue building a world-class team, accelerate product development and commercialize its computer vision sensing and processing technology. The funding will also allow the company to expand into key markets, including the US and Asia.
Chronocam’s proprietary approach leverages the company’s deep expertise in computer vision technology, sensor design and neuromorphic computing, which mimics the human brain. The Chronocam method uses innovative data capture techniques to greatly improve performance, dynamic range and power efficiency of cameras in a wide range of applications.
“C chanel sac pas cher onventional computer vision approaches are not well-suited to the requirements of a new generation of vision-enabled systems,” said Luca Verre, CEO and co-founder of Chronocam. “Chronocam’s unique bio-inspired technology introduces a new paradigm in capturing and processing visual data, and addresses the most pressing market challenges head-on,” Verre continued. We are well-positioned to capitalize on this significant market opportunity; and we appreciate the confidence demonstrated by our investors as we roll out our technology to an increasing number of customers.”